Given the pathological heterogeneity between AQP4-IgG positive and negative neuromyelitis optica spectrum disorder (NMOSD), only AQP4-IgG–positive patients were enrolled to ensure cohort homogeneity. This evidence concerns the gene AQP4 and neuromyelitis optica.